
Cancer: Ovarian
https://www.facingourrisk.org/research-clinical-trials/study/361 /testing-olaparib-for-one-or-two-years-with-or-without-bevacizumab-to-treat-ovarian-cancer-with-a-brca-mutation-or-a-biomarker-called-hrd
Clinicaltrials.gov identifier:
NCT06580314 (https://clinicaltrials.gov/show/NCT06580314)
Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD
https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations
Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/350 /treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Clinicaltrials.gov identifier:
NCT06167317 (https://clinicaltrials.gov/show/NCT06167317)
Treatment
Treatment study for people with advanced or metastatic solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/101 /a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock
Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
https://www.facingourrisk.org/research-clinical-trials/study/334 /study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer
Clinicaltrials.gov identifier:
NCT05281471 (https://clinicaltrials.gov/show/NCT05281471)
Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy
https://www.facingourrisk.org/research-clinical-trials/study/335 /understanding-the-emotional-and-social-experiences-of-individuals-living-with-ovarian-cancer
Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer
https://www.facingourrisk.org/research-clinical-trials/study/311 /study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Clinicaltrials.gov identifier:
NCT06022029 (https://clinicaltrials.gov/show/NCT06022029)
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/138 /validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
https://www.facingourrisk.org/research-clinical-trials/study/205 /risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women
Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)
Prevention
Prevention study for women at high risk for ovarian cancer
https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)
Treatment
Cancer treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/247 /self-perception-and-intimacy-after-the-cancer-experience-spice
Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health
https://www.facingourrisk.org/research-clinical-trials/study/248 /cancer-experience-registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
https://www.facingourrisk.org/research-clinical-trials/study/157 /treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Clinicaltrials.gov identifier:
NCT04657068 (https://clinicaltrials.gov/show/NCT04657068)
Treatment
Phase 1/2 treatment study for advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/84 /ellies-project
Quality of Life
A survey for people with a hereditary cancer genetic mutation
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.